Sermorelin and CJC-1295 are both GHRH analogs — they share the same basic mechanism of nudging the pituitary to release growth hormone along its natural pathway. The practical difference is durability. Sermorelin is short-acting and closely mirrors natural GHRH; CJC-1295, especially in its "DAC" (Drug Affinity Complex) form, was engineered to last far longer in the body, extending the growth-hormone signal. Sermorelin also has a formal regulatory history that CJC-1295 lacks.
At a glance
| Sermorelin | CJC-1295 | |
|---|---|---|
| Class | GHRH analog (GHRH 1–29) | GHRH analog (often with DAC) |
| Duration of action | Short-acting | Long-acting with DAC; short without |
| Regulatory history | Formerly FDA-approved (Geref) | Research chemical only |
| Mechanism | Stimulates pituitary GH release | Stimulates pituitary GH release, longer signal |
| FDA status (now) | Compounded / research | Not approved (research chemical) |
| Sport status | Banned (WADA) | Banned (WADA) |
The bottom line
Bottom line: Same family, different half-life. Sermorelin is the shorter-acting, more "physiological" GHRH analog with a regulatory pedigree; CJC-1295 with DAC trades that short pulse for a sustained signal. Neither is an approved performance or anti-aging therapy today, and both are prohibited in sport.
Frequently asked questions
What is the difference between sermorelin and CJC-1295?
Both are GHRH analogs, but sermorelin is short-acting while CJC-1295 — particularly with DAC — is engineered to last much longer, producing a more sustained growth-hormone signal.
What does 'DAC' mean on CJC-1295?
DAC stands for Drug Affinity Complex, a modification that binds the peptide to albumin in the blood so it lasts far longer than unmodified GHRH analogs like sermorelin. CJC-1295 without DAC is short-acting.
Is sermorelin or CJC-1295 approved?
Sermorelin was previously FDA-approved (as Geref) and is now usually compounded; CJC-1295 has only ever been a research chemical. Neither is an approved muscle or anti-aging therapy, and both are banned in sport.
References
Combined peer-reviewed sources from both peptide guides. Inclusion is not endorsement.
- Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006. Peer-reviewed study
- Kerrigan JR, Martha PM Jr, Blizzard RM, et al. Treatment with GHRH(1-29)NH2 in children with idiopathic short stature induces a sustained increase in growth velocity. J Clin Endocrinol Metab. 1994. Peer-reviewed study
- Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999. Peer-reviewed study
- Chang Y, Huang R, Zhai Y, et al. A potentially effective drug for patients with recurrent glioma: sermorelin. Ann Transl Med. 2021. Peer-reviewed study
- Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006. Peer-reviewed study
- Jette L, Leger R, Thibaudeau K, et al. hGRF(1-29)-albumin bioconjugates activate the GRF receptor: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005. Peer-reviewed study
- Timms M, Ganio K, Steel R. A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS. Drug Test Anal. 2019. Peer-reviewed study
- Van Hout MC, Hearne E. Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Subst Use Misuse. 2016. Peer-reviewed study
- Timms M, Ganio K, Forbes G, et al. An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma. Drug Test Anal. 2019. Peer-reviewed study
- Alba M, Fintini D, Sagazio A, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006. Peer-reviewed study